x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Pigment Epithelium Derived Factor (PEDF), as a multifunctional endogenous protein, can precisely regulate the core pathological processes of diabetes and its vascular complications through its unique anti-inflammatory, antioxidant, anti-angiogenic and neurotrophic effects. This property makes PEDF an promising therapeutic target for combating microvascular complications such as diabetic retinopathy and nephropathy. Ace Therapeutics provides end-to-end solutions for anti-diabetic drug development targeting PEDF. Our services span from early-stage target mechanism studies and lead compound optimization to comprehensive pharmacodynamic evaluations and safety investigations. Leveraging validated animal models of diabetic complications and proven preclinical translation expertise, we are committed to accelerating the development of our clients' innovative therapeutics.
Pigment Epithelium Derived Factor (PEDF) is a protein isolated from retinal pigment epithelial cells that has multiple functions including neuronal protection, anti-tumor effects and anti-inflammatory activity. Studies have shown that PEDF prevents HFD-induced obesity and metabolic disorders, inhibits adipogenesis, and ameliorates insulin resistance in mice. These results provide new potential treatments for diabetes-related obesity.
Fig. 1 The summary of PEDF targets multiple pathways exerting pleiotropic functions in the pathology of diabetic retinopathy. (Liu, X.; et al., 2013)
Leveraging the central regulatory role of pigment epithelium-derived factor (PEDF) in diabetic microvascular complications, Ace Therapeutics provides end-to-end preclinical drug discovery and development services to accelerate the discovery of innovative antidiabetic therapeutics for clients.
We clarify the mechanism of action of PEDF in diabetes through gene editing and signaling pathway analysis.
We use high glucose-induced cellular models and diabetic animal models (e.g., db/db mice, ZDF rats) to assess the metabolic improvement effect of PEDF regulation.
Small molecule agonist development: virtual screening and structure optimization based on PEDF receptor binding domain.
Biomolecule drugs: development of PEDF-mimetic peptides, recombinant proteins or antibody drugs.
Insulin resistance model (e.g., HFD/STZ-induced mice): we assessed the effects of PEDF drugs on blood glucose, insulin sensitivity.
β-cell protection model (e.g. db/db mice): we test the protective effect of the drug on islet function and apoptosis.
Glucose tolerance (OGTT), insulin tolerance (ITT)
Serum lipocalin, inflammatory factors (e.g. TNF-α, IL-6) levels
Ace Therapeutics delivers efficient and reliable end-to-end preclinical antidiabetic drug development services to accelerate your project progression. With in-depth target expertise, customized research solutions, and highly predictive models, we support novel PEDF-targeted antidiabetic drug development. Regardless of your current stage in drug discovery, we provide professional technical support and flexible collaboration models. Contact us today to learn more details.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
